Clinical trialNCT03556228RecruitingPhase 1/PHASE2Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

SponsorVM Oncology, LLCEnrollment242Adenoid Cystic CarcinomaAny Solid Tumors Progressed After a Prior ImmunotherapyEsophageal CancerHead and Neck CancersHead and Neck Cancers - NasopharyngealHead and Neck Cancers - Salivary Gland+19 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Clinical Development
VM Oncology
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Panoncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200)
San Juan, Puerto Rico
Marcia Cruz-Correa, MD, PhD, AGAF, FASGE
Recruiting

United States

Providence Medical Foundation (site 209)
Santa Rosa, California, United States
Ian C Anderson, MD
Recruiting
Hartford Hospital (site 210)
Hartford, Connecticut, United States
Jaykumar Thumar, MD
Recruiting
the George Washington University Cancer Center (site 212)
Washington D.C., District of Columbia, United States
Sonal Paul, MD
Recruiting
Holy Cross Hospital (site 213)
Fort Lauderdale, Florida, United States
Georges Azzi, MD
Recruiting
Memorial Cancer Institute at Memorial Healthcare Systems (site 132)
Pembroke Pines, Florida, United States
Luis E Raez, MD
Recruiting
Englewood Hospital and Medical Center (site 202)
Englewood, New Jersey, United States
Minaxi Jhawer, MD
Recruiting
Summit Medical Group (site 205)
Florham Park, New Jersey, United States
David Gallinson, DO
Recruiting
Atlantic Health System, Morristown Medical Center (site 124)
Morristown, New Jersey, United States
Angela Alistar, MD
Recruiting
Presbyterian Kaseman Hospital (site 208)
Albuquerque, New Mexico, United States
Ethan Binder, MD
Recruiting
Weill Cornell Medicine, Cornell University (site 126)
New York, New York, United States
Barbara Ma, M.D., M.S.
Recruiting
Taylor Cancer Research Center (site 204)
Maumee, Ohio, United States
John J Nemunaitis, MD
Recruiting
Cancer Care Associates of York (site 206)
York, Pennsylvania, United States
Chanh Huynh, MD
Recruiting
the University of Texas Md Anderson Cancer Center (site 127)
Houston, Texas, United States
David S Hong, MD
Recruiting
Utah Cancer Specialists (site 203)
Salt Lake City, Utah, United States
Stephan DiSean Kendall, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acidVMD-928 and Pembrolizumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jun 2018
Primary completion: 31 Dec 2027
Completion: 30 Jun 2028
Last update posted: 11 Dec 2025
Registered enrollment: 242
Registry id: NCT03556228

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.